Global pharma major Lupin Limited (Lupin) today announced that it has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical Company Limited (Takeda), to commercialize Vonoprazan Tablets in the Indian market. The drug will be marketed under the brand name Lupin's Lupivon® and will be available in two strengths - 10 mg and 20 mg.
Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India.
"We are very pleased to commercialize Vonoprazan, a novel treatment option for Acid Peptic Disorders. This is a further step in strengthening our gastroenterology portfolio and is in line with our commitment to introduce innovative medicines to address unmet needs of our patients," said, Rajeev Sibal, President India Region Formulations, Lupin.
Acid Peptic Disorder (APD) which includes Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD), is a highly prevalent disorder in India. While prevalence of GERD ranges from 5% to 28.5%, PUD has prevalence in the range of ~ 8%. Risk factors for GERD include old age, high body mass index (BMI), non-vegetarian diet, tea/coffee intake, smoking and alcohol consumption.
Shares of Lupin Limited was last trading in BSE at Rs. 2270.60 as compared to the previous close of Rs. 2252.25. The total number of shares traded during the day was 15333 in over 1801 trades.
The stock hit an intraday high of Rs. 2285.95 and intraday low of 2240.40. The net turnover during the day was Rs. 34831509.00. |
